Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA-2)

Open to people ages 18-79

• Histologically confirmed diagnosis of relapsed/refractory large B-cell lymphoma at last relapse.
• At least 1 measurable lesion at time of enrollment.
• Relapsed or refractory disease after at least 2 lines of chemotherapy
• ECOG performance status 0 or 1.
• Absence of donor (product)-specific anti-HLA antibodies (DSA).
• Adequate hematological, renal and liver function.

• Current or history of central nervous system (CNS) lymphoma.
• Clinically significant CNS dysfunction
• Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.
• Radiation therapy within 2 weeks prior to ALLO-647.
• Prior irradiation to >25% of the bone marrow.
• Donor lymphocyte infusion (DLI) within 30 days prior to ALLO-647.
• Patients unwilling to participate in an extended safety monitoring period